Lp-PLA2-IN-1
CAS No. 1420367-28-7
Lp-PLA2-IN-1 ( Lp-PLA2 -IN-1 | Lp-PLA2 inhibitor 1 )
产品货号. M26743 CAS No. 1420367-28-7
Lp-PLA2 -IN-1 抑制 Lp-PLA2 活性过程以进行制备。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥701 | 有现货 |
|
| 10MG | ¥1131 | 有现货 |
|
| 25MG | ¥1981 | 有现货 |
|
| 50MG | ¥2995 | 有现货 |
|
| 100MG | ¥4059 | 有现货 |
|
| 200MG | ¥5355 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Lp-PLA2-IN-1
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Lp-PLA2 -IN-1 抑制 Lp-PLA2 活性过程以进行制备。
-
产品描述Lp-PLA2 -IN-1 suppresses Lp-PLA2 activity processes for their preparation. Lp-PLA2 -IN-1also inhibits to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example, atherosclerosis, Alzheimer's disease.(In Vitro):Lp-PLA2 is a phospholipase A2 enzyme involved in the hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2 travels with LDL and rapidly cleaves oxidized phosphatidylcholine molecules derived from the oxidation of LDL.
-
体外实验Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2 travels with low-density lipoprotein (LDL) and rapidly cleaves oxidized phosphatidylcholine molecules derived from the oxidation of LDL.
-
体内实验——
-
同义词Lp-PLA2 -IN-1 | Lp-PLA2 inhibitor 1
-
通路Metabolic Enzyme/Protease
-
靶点Phospholipase
-
受体Androgen Receptor
-
研究领域——
-
适应症——
化学信息
-
CAS Number1420367-28-7
-
分子量468.384
-
分子式C21H17F5N4O3
-
纯度>98% (HPLC)
-
溶解度In Vitro:?Ethanol : 25 mg/mL (53.38 mM)
-
SMILESCN1CCCn2c1cc(OCc1cc(F)c(Oc3ccc(nc3)C(F)(F)F)c(F)c1)nc2=O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Cutler C, et al. Equine metabolism of the selective androgen receptor modulator AC-262536 in vitro and in urine, plasma and hair following oral administration. Drug Test Anal. 2021 Feb;13(2):369-385.
产品手册
关联产品
-
VU0359595
VU0359595 (CID-53361951; ML-270) 是一种选择性磷脂酶 D1 (PLD1) 抑制剂,IC50 值为 3.7 nM。VU0359595 对 PLD1 的选择性比 PLD2 (IC50=6.4 μM) 高 1700 倍以上。VU0359595 可用于癌症、糖尿病、神经退行性疾病和炎性疾病等疾病研究。
-
Uric Acid
通过黄嘌呤氧化酶产生的氧化产物,如黄嘌呤和次黄嘌呤。
-
Linocinnamarin
Linocinamarin 是从 Fragaria ananassa Duch 中分离出来的。 LN 对抗原刺激的脱颗粒的抑制主要是由于 Syk/磷脂酶 Cgamma (PLCgamma) 途径的失活。
021-51111890
购物车()
sales@molnova.cn

